U.S. Markets close in 11 mins

Equillium to Present at Leerink Partners Global Healthcare Conference

LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce Steel, Equillium’s president and chief business officer, will present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, February 28, 2019. 

Date:   Thursday, February 28, 2019
Time:   10:00 AM Eastern Time | 7:00 AM Pacific Time
Location:   Lotte New York Palace in New York, NY

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.

About Equillium
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.

Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the activity and trafficking of Teff cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to EQ001 through an exclusive partnership with Biocon Limited. Equillium believes that EQ001 has the potential to be a best-in-class disease modifying therapeutic and is advancing EQ001 into clinical development in multiple immuno-inflammatory indications with high unmet medical need. For more information, visit www.equilliumbio.com.

Investor Contact

Media Contact
Heidi Chokeir, Ph.D.
Canale Communications